Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Localized scleroderma.

Ronald M Laxer1, Francesco Zulian

  • 1Department of Paediatrics and Medicine, University of Toronto, Vice President, Education and Quality, The Hospital for Sick Children, Toronto, Canada. ronald.laxer@sickkids.ca

Current Opinion in Rheumatology
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baricitinib in Two Pediatric Patients with COPA syndrome: A Case Series and Literature Review.

Modern rheumatology case reports·2026
Same author

Pediatric morphea: MRI evaluation of superficial and deep tissue involvement and impact in clinical practice.

Pediatric radiology·2026
Same author

Psoriatic arthritis spectrum in children: a multicentre observational study.

Clinical and experimental rheumatology·2026
Same author

"Adnexotropic" lichen striatus: a potential histological mimicker of mycosis fungoides.

Pathologica·2026
Same author

Differentiating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) and Syndrome of Undifferentiated Recurrent Fever (SURF): A Comparative Study of Clinical Features, Treatment Response, and Remission.

The Journal of rheumatology·2026
Same author

Systemic Sclerosis Without Raynaud Phenomenon in Children: The Fibrotic Subtype.

The Journal of rheumatology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Localized scleroderma (morphoea) presents diverse symptoms, sometimes affecting the whole body. Early diagnosis and treatment of this condition are crucial for better long-term outcomes, especially in children.

Area of Science:

  • Dermatology
  • Rheumatology
  • Pediatrics

Background:

  • Localized scleroderma, or morphoea, exhibits varied clinical presentations.
  • Systemic involvement can occur, necessitating comprehensive evaluation.
  • Early intervention is key to improving patient prognosis.

Purpose of the Study:

  • To review recent findings on localized scleroderma, focusing on juvenile cases.
  • To highlight the spectrum of clinical manifestations, including extracutaneous involvement.
  • To assess the efficacy of current and emerging treatments.

Main Methods:

  • Analysis of a large multicenter study on juvenile localized scleroderma.
  • Review of existing literature on treatment efficacy, including methotrexate, corticosteroids, and phototherapy.

Related Experiment Videos

  • Examination of preliminary data on novel immunomodulators like imiquimod.

    • Main Results:

    • Confirmed efficacy of methotrexate and corticosteroids in treating localized scleroderma.
    • Phototherapy demonstrated significant therapeutic benefits.
    • Imiquimod shows potential as a promising treatment in early case studies.
    • Epidemiological data and clinical manifestations, particularly systemic ones, were elucidated.

    Conclusions:

    • Recent studies underscore the broad range of extracutaneous manifestations in localized scleroderma.
    • Different clinical forms of the condition have been identified.
    • Treatment interventions for localized scleroderma appear beneficial, potentially improving long-term outcomes.